

PATIENT NAME : DINESH JHA

REF. DOCTOR : SELF

400089
Mumbai 400089

ACCESSION NO : 0002WD005640

PATIENT ID : DINEM05108827

CLIENT PATIENT ID:

ABHA NO :

AGE/SEX : 34 Years Male

DRAWN : 04/04/2023 10:28:15

RECEIVED : 04/04/2023 10:30:05

REPORTED : 05/04/2023 15:33:27

Test Report Status **Final**

Results

Biological Reference Interval Units

MEDI WHEEL FULL BODY HEALTH CHECK UP BELOW 40 MALE**XRAY-CHEST**

IMPRESSION

NO ABNORMALITY DETECTED

TMT OR ECHO

TMT OR ECHO

2 DECHO DONE :
NO REGIONAL WALL MOTION ABNORMALITY AT REST.
NORMAL LV AND RV SYSTOLIC FUNCTION.
OVERALL LVEF: 55-60%.
NORMAL LV DIASTOLIC FUNCTION.**ECG**

ECG

WITHIN NORMAL LIMITS

MEDICAL HISTORY

RELEVANT PRESENT HISTORY

RAISED TRIGLYCERIDE
ACIDITY ON AND OFF

RELEVANT PAST HISTORY

COVID 19 IN 2021
JAUNDICE IN CHILDHOOD
OPERTAED LIPOMA ON HAND BILATERALY 2021

RELEVANT PERSONAL HISTORY

ALCOHOL- OCC

RELEVANT FAMILY HISTORY

NOT SIGNIFICANT

HISTORY OF MEDICATIONS

NOT SIGNIFICANT

ANTHROPOMETRIC DATA & BMI

HEIGHT IN METERS

1.73

mts

WEIGHT IN KGS.

74.1

Kgs

BMI

25

BMI & Weight Status as follows/sqmts
Below 18.5: Underweight
18.5 - 24.9: Normal
25.0 - 29.9: Overweight
30.0 and Above: Obese**GENERAL EXAMINATION**

MENTAL / EMOTIONAL STATE

NORMAL

PHYSICAL ATTITUDE

NORMAL

GENERAL APPEARANCE / NUTRITIONAL
STATUS

HEALTHY

BUILT / SKELETAL FRAMEWORK


AVERAGE

FACIAL APPEARANCE

NORMAL

SKIN

NORMAL


Dr. J N Shukla ,MBBS, AFIH
Consultant Physician

Page 1 Of 24



View Details



View Report

PERFORMED AT :SRL Ltd
PRIME SQUARE BUILDING,PLOT NO 1,GAIWADI INDUSTRIAL ESTATE,S.V. ROAD,GOREGAON (W)
Mumbai, 400062
MAHARASHTRA, INDIA
Tel : 9111591115, Fax :
CIN - U74899PB1995PLC045956

Patient Ref. No. 2000011707303

PATIENT NAME : DINESH JHA

REF. DOCTOR : SELF

400089
Mumbai 400089ACCESSION NO : **0002WD005640**

AGE/SEX : 34 Years Male

PATIENT ID : DINEM05108827

DRAWN : 04/04/2023 10:28:15

CLIENT PATIENT ID:


RECEIVED : 04/04/2023 10:30:05

ABHA NO :

REPORTED : 05/04/2023 15:33:27

| Test Report Status | Final | Results | Biological Reference Interval | Units |
|--------------------|-------|---------|-------------------------------|-------|
|--------------------|-------|---------|-------------------------------|-------|

| | | | |
|-----------------------------------|---|--|-------|
| UPPER LIMB | NORMAL | | |
| LOWER LIMB | NORMAL | | |
| NECK | NORMAL | | |
| NECK LYMPHATICS / SALIVARY GLANDS | NOT ENLARGED OR TENDER | | |
| THYROID GLAND | NOT ENLARGED | | |
| CAROTID PULSATION | NORMAL | | |
| TEMPERATURE | NORMAL | | |
| PULSE | 76/MIN REGULAR, ALL PERIPHERAL PULSES WELL FELT, NO CAROTID BRUIT | | |
| RESPIRATORY RATE | NORMAL | | |
| CARDIOVASCULAR SYSTEM | | | |
| BP | 124/82 MM HG (SUPINE) | | mm/Hg |
| PERICARDIUM | NORMAL | | |
| APEX BEAT | NORMAL | | |
| HEART SOUNDS | S1, S2 HEARD NORMALLY | | |
| MURMURS | ABSENT | | |
| RESPIRATORY SYSTEM | | | |
| SIZE AND SHAPE OF CHEST | NORMAL | | |
| MOVEMENTS OF CHEST | SYMMETRICAL | | |
| BREATH SOUNDS INTENSITY | NORMAL | | |
| BREATH SOUNDS QUALITY | VESICULAR (NORMAL) | | |
| ADDED SOUNDS | ABSENT | | |
| PER ABDOMEN | | | |
| APPEARANCE | NORMAL | | |
| VENOUS PROMINENCE | ABSENT | | |
| LIVER | NOT PALPABLE | | |
| SPLEEN | NOT PALPABLE | | |
| HERNIA | ABSENT | | |
| CENTRAL NERVOUS SYSTEM | | | |
| HIGHER FUNCTIONS | NORMAL | | |
| CRANIAL NERVES | NORMAL | | |
| CEREBELLAR FUNCTIONS | NORMAL | | |



Dr. J N Shukla ,MBBS, AFIH
Consultant Physician

Page 2 Of 24



View Details



View Report

PERFORMED AT :

SRL Ltd
PRIME SQUARE BUILDING,PLOT NO 1,GAIWADI INDUSTRIAL ESTATE,S.V. ROAD,GOREGAON (W)
Mumbai, 400062
MAHARASHTRA, INDIA
Tel : 9111591115, Fax :
CIN - U74899PB1995PLC045956



Patient Ref. No. 2000011707303

PATIENT NAME : DINESH JHA

REF. DOCTOR : SELF

400089
Mumbai 400089ACCESSION NO : **0002WD005640**

AGE/SEX : 34 Years Male

PATIENT ID : DINEM05108827

DRAWN : 04/04/2023 10:28:15

CLIENT PATIENT ID:


RECEIVED : 04/04/2023 10:30:05

ABHA NO :

REPORTED : 05/04/2023 15:33:27

| Test Report Status | Final | Results | Biological Reference Interval | Units |
|--------------------|-------|---------|-------------------------------|-------|
|--------------------|-------|---------|-------------------------------|-------|

| | |
|---------------------------------------|---|
| SENSORY SYSTEM | NORMAL |
| MOTOR SYSTEM | NORMAL |
| REFLEXES | NORMAL |
| MUSCULOSKELETAL SYSTEM | |
| SPINE | NORMAL |
| JOINTS | NORMAL |
| BASIC EYE EXAMINATION | |
| CONJUNCTIVA | NORMAL |
| EYELIDS | NORMAL |
| EYE MOVEMENTS | NORMAL |
| CORNEA | NORMAL |
| DISTANT VISION RIGHT EYE WITH GLASSES | WITH GLASSES NORMAL (6/6) |
| DISTANT VISION LEFT EYE WITH GLASSES | WITH GLASSES NORMAL (6/6) |
| NEAR VISION RIGHT EYE WITHOUT GLASSES | WITHIN NORMAL LIMIT (N6) |
| NEAR VISION LEFT EYE WITHOUT GLASSES | WITHIN NORMAL LIMIT (N6) |
| COLOUR VISION | NORMAL (17/17) |
| BASIC ENT EXAMINATION | |
| EXTERNAL EAR CANAL | NORMAL |
| TYMPANIC MEMBRANE | NORMAL |
| NOSE | NO ABNORMALITY DETECTED |
| SINUSES | NORMAL |
| THROAT | NO ABNORMALITY DETECTED |
| TONSILS | NOT ENLARGED |
| BASIC DENTAL EXAMINATION | |
| TEETH | NORMAL |
| GUMS | HEALTHY |
| SUMMARY | |
| RELEVANT HISTORY | NOT SIGNIFICANT |
| RELEVANT GP EXAMINATION FINDINGS | NOT SIGNIFICANT |
| RELEVANT LAB INVESTIGATIONS | RAISED BASOPHIL (4) RAISED TRYGLYCERIDE (216) RAISED SGPT (48) RAISED GGT (72) |



Dr. J N Shukla ,MBBS, AFIH
Consultant Physician

Page 3 Of 24



View Details



View Report

PERFORMED AT :

SRL Ltd
PRIME SQUARE BUILDING,PLOT NO 1,GAIWADI INDUSTRIAL ESTATE,S.V. ROAD,GOREGAON (W)
Mumbai, 400062
MAHARASHTRA, INDIA
Tel : 9111591115, Fax :
CIN - U74899PB1995PLC045956



Patient Ref. No. 2000011707303

PATIENT NAME : DINESH JHA

REF. DOCTOR : SELF

400089
Mumbai 400089ACCESSION NO : **0002WD005640**

PATIENT ID : DINEM05108827

CLIENT PATIENT ID:

ABHA NO :

AGE/SEX : 34 Years Male

DRAWN : 04/04/2023 10:28:15


RECEIVED : 04/04/2023 10:30:05

REPORTED : 05/04/2023 15:33:27

| Test Report Status | Final | Results | Biological Reference Interval | Units |
|--------------------|-------|---------|-------------------------------|-------|
|--------------------|-------|---------|-------------------------------|-------|

RELEVANT NON PATHOLOGY DIAGNOSTICS
REMARKS / RECOMMENDATIONS

USG- GRADE I FATTY LIVER
 ALTER BLOOD LIPID , RAISED BASOPHIL
 RDEUCE PROCESSED FOOD AND ALCOHOLIC DRUGS
 ADV- VIATMIN D AND VIATMIN B12 TEST
 REAPT CBS FOR BASOPHIL
 FOLLOW UP WITH PHYSICIAN FOR RAISED BASOPHIL COUNT


Dr. J N Shukla ,MBBS, AFIH
Consultant Physician

Page 4 Of 24



View Details



View Report

PERFORMED AT :

SRL Ltd
 PRIME SQUARE BUILDING,PLOT NO 1,GAIWADI INDUSTRIAL ESTATE,S.V. ROAD,GOREGAON (W)
 Mumbai, 400062
 MAHARASHTRA, INDIA
 Tel : 9111591115, Fax :
 CIN - U74899PB1995PLC045956



Patient Ref. No. 2000011707303

PATIENT NAME : DINESH JHA

REF. DOCTOR : SELF

400089
Mumbai 400089

ACCESSION NO : **0002WD005640**
PATIENT ID : DINEM05108827
CLIENT PATIENT ID:
ABHA NO :

AGE/SEX : 34 Years Male
DRAWN : 04/04/2023 10:28:15
RECEIVED : 04/04/2023 10:30:05
REPORTED : 05/04/2023 15:33:27

| Test Report Status | Final | Results | Units |
|--------------------|-------|---------|-------|
|--------------------|-------|---------|-------|

MEDI WHEEL FULL BODY HEALTH CHECK UP BELOW 40 MALE

ULTRASOUND ABDOMEN

ULTRASOUND ABDOMEN

- GRADE I FATTY LIVER.

Interpretation(s)

MEDICAL

HISTORY*****

THIS REPORT CARRIES THE SIGNATURE OF OUR LABORATORY DIRECTOR. THIS IS AN INVIOABLE FEATURE OF OUR LAB MANAGEMENT SOFTWARE. HOWEVER, ALL EXAMINATIONS AND INVESTIGATIONS HAVE BEEN CONDUCTED BY OUR PANEL OF DOCTORS.

**Dr. J N Shukla ,MBBS, AFIH
Consultant Physician**



View Details



View Report

PERFORMED AT :

SRL Ltd
PRIME SQUARE BUILDING,PLOT NO 1,GAIWADI INDUSTRIAL ESTATE,S.V. ROAD,GOREGAON (W)
Mumbai, 400062
MAHARASHTRA, INDIA
Tel : 9111591115, Fax :
CIN - U74899PB1995PLC045956



Patient Ref. No. 2000011707303



PATIENT NAME : DINESH JHA

REF. DOCTOR : SELF

400089
Mumbai 400089
 ACCESSION NO : **0002WD005640**
 PATIENT ID : DINEM05108827
 CLIENT PATIENT ID:
 ABHA NO :

 AGE/SEX : 34 Years Male
 DRAWN : 04/04/2023 10:28:15
 RECEIVED : 04/04/2023 10:30:05
 REPORTED : 05/04/2023 15:33:27

| Test Report Status | Final | Results | Biological Reference Interval | Units |
|--------------------|-------|---------|-------------------------------|-------|
|--------------------|-------|---------|-------------------------------|-------|

HAEMATOLOGY - CBC

MEDI WHEEL FULL BODY HEALTH CHECK UP BELOW 40 MALE

BLOOD COUNTS, EDTA WHOLE BLOOD

| | | | |
|--|------|-------------|---------------|
| HEMOGLOBIN (HB) | 13.5 | 13.0 - 17.0 | g/dL |
| METHOD : PHOTOMETRIC MEASUREMENT | | | |
| RED BLOOD CELL (RBC) COUNT | 4.68 | 4.5 - 5.5 | mil/ μ L |
| METHOD : COULTER PRINCIPLE | | | |
| WHITE BLOOD CELL (WBC) COUNT | 4.20 | 4.0 - 10.0 | thou/ μ L |
| METHOD : COULTER PRINCIPLE | | | |
| PLATELET COUNT | 195 | 150 - 410 | thou/ μ L |
| METHOD : ELECTRONIC IMPEDENCE & MICROSCOPY | | | |

RBC AND PLATELET INDICES

| | | | |
|--|------------------|--------------|------|
| HEMATOCRIT (PCV) | 40.4 | 40.0 - 50.0 | % |
| METHOD : CALCULATED PARAMETER | | | |
| MEAN CORPUSCULAR VOLUME (MCV) | 86.2 | 83.0 - 101.0 | fL |
| METHOD : DERIVED PARAMETER FROM RBC HISTOGRAM | | | |
| MEAN CORPUSCULAR HEMOGLOBIN (MCH) | 28.8 | 27.0 - 32.0 | pg |
| METHOD : CALCULATED PARAMETER | | | |
| MEAN CORPUSCULAR HEMOGLOBIN CONCENTRATION (MCHC) | 33.4 | 31.5 - 34.5 | g/dL |
| METHOD : CALCULATED PARAMETER | | | |
| RED CELL DISTRIBUTION WIDTH (RDW) | 13.9 | 11.6 - 14.0 | % |
| METHOD : DERIVED PARAMETER FROM RBC HISTOGRAM | | | |
| MENTZER INDEX | 18.4 | | |
| MEAN PLATELET VOLUME (MPV) | 11.0 High | 6.8 - 10.9 | fL |
| METHOD : DERIVED PARAMETER FROM PLATELET HISTOGRAM | | | |

WBC DIFFERENTIAL COUNT

| | | | |
|--------------------------------------|----|------------|---|
| NEUTROPHILS | 52 | 40 - 80 | % |
| METHOD : VCSN TECHNOLOGY/ MICROSCOPY | | | |
| LYMPHOCYTES | 33 | 20 - 40 | % |
| METHOD : VCSN TECHNOLOGY/ MICROSCOPY | | | |
| MONOCYTES | 8 | 2.0 - 10.0 | % |
| METHOD : VCSN TECHNOLOGY/ MICROSCOPY | | | |
| EOSINOPHILS | 3 | 1.0 - 6.0 | % |
| METHOD : VCSN TECHNOLOGY/ MICROSCOPY | | | |

 Dr. Reena Mittal, MD
 Senior Consultant
 Hematopathologist

 Dr. Sushant Chikane
 Consultant Pathologist

Page 6 Of 24



View Details



View Report

PERFORMED AT :

 SRL Ltd
 PRIME SQUARE BUILDING, PLOT NO 1, GAIWADI INDUSTRIAL ESTATE, S.V. ROAD, GOREGAON (W)
 Mumbai, 400062
 MAHARASHTRA, INDIA
 Tel : 9111591115, Fax :
 CIN - U74899PB1995PLC045956


Patient Ref. No. 2000011707303



MC-2010

PATIENT NAME : DINESH JHA

REF. DOCTOR : SELF

400089
Mumbai 400089

ACCESSION NO : 0002WD005640

PATIENT ID : DINEM05108827

CLIENT PATIENT ID:

ABHA NO :

AGE/SEX : 34 Years Male

DRAWN : 04/04/2023 10:28:15

RECEIVED : 04/04/2023 10:30:05

REPORTED : 05/04/2023 15:33:27

| Test Report Status | Final | Results | Biological Reference Interval | Units |
|--------------------------------------|-------|------------------|-------------------------------|---------------|
| BASOPHILS | | 4 High | 0 - 1 | % |
| METHOD : VCSN TECHNOLOGY/ MICROSCOPY | | | | |
| ABSOLUTE NEUTROPHIL COUNT | | 2.20 | 2.0 - 7.0 | thou/ μ L |
| METHOD : CALCULATED PARAMETER | | | | |
| ABSOLUTE LYMPHOCYTE COUNT | | 1.40 | 1.0 - 3.0 | thou/ μ L |
| METHOD : CALCULATED PARAMETER | | | | |
| ABSOLUTE MONOCYTE COUNT | | 0.34 | 0.2 - 1.0 | thou/ μ L |
| METHOD : CALCULATED PARAMETER | | | | |
| ABSOLUTE EOSINOPHIL COUNT | | 0.13 | 0.02 - 0.50 | thou/ μ L |
| METHOD : CALCULATED PARAMETER | | | | |
| ABSOLUTE BASOPHIL COUNT | | 0.17 High | 0.02 - 0.10 | thou/ μ L |
| METHOD : CALCULATED PARAMETER | | | | |
| NEUTROPHIL LYMPHOCYTE RATIO (NLR) | | 1.6 | | |
| METHOD : CALCULATED | | | | |

Interpretation(s)

BLOOD COUNTS, EDTA WHOLE BLOOD-The cell morphology is well preserved for 24hrs. However after 24-48 hrs a progressive increase in MCV and HCT is observed leading to a decrease in MCHC. A direct smear is recommended for an accurate differential count and for examination of RBC morphology.

RBC AND PLATELET INDICES-Mentzer index (MCV/RBC) is an automated cell-counter based calculated screen tool to differentiate cases of Iron deficiency anaemia (>13) from Beta thalassaemia trait

(<13) in patients with microcytic anaemia. This needs to be interpreted in line with clinical correlation and suspicion. Estimation of HbA2 remains the gold standard for diagnosing a case of beta thalassaemia trait.

WBC DIFFERENTIAL COUNT-The optimal threshold of 3.3 for NLR showed a prognostic possibility of clinical symptoms to change from mild to severe in COVID positive patients. When age = 49.5 years old and NLR = 3.3, 46.1% COVID-19 patients with mild disease might become severe. By contrast, when age < 49.5 years old and NLR < 3.3, COVID-19 patients tend to show mild disease.

(Reference to - The diagnostic and predictive role of NLR, d-NLR and PLR in COVID-19 patients ; A.-P. Yang, et al.; International Immunopharmacology 84 (2020) 106504 This ratio element is a calculated parameter and out of NABL scope.

Dr. Reena Mittal, MD
Senior Consultant
Hematopathologist

Dr. Sushant Chikane
Consultant Pathologist

Page 7 Of 24



View Details



View Report

PERFORMED AT :

SRL Ltd
PRIME SQUARE BUILDING, PLOT NO 1, GAIWADI INDUSTRIAL ESTATE, S.V. ROAD, GOREGAON (W)
Mumbai, 400062
MAHARASHTRA, INDIA
Tel : 9111591115, Fax :
CIN - U74899PB1995PLC045956



Patient Ref. No. 2000011707303



PATIENT NAME : DINESH JHA

REF. DOCTOR : SELF

400089
Mumbai 400089
 ACCESSION NO : **0002WD005640**
 PATIENT ID : DINEM05108827
 CLIENT PATIENT ID:
 ABHA NO :

 AGE/SEX : 34 Years Male
 DRAWN : 04/04/2023 10:28:15
 RECEIVED : 04/04/2023 10:30:05
 REPORTED : 05/04/2023 15:33:27

| Test Report Status | Final | Results | Biological Reference Interval | Units |
|--------------------|-------|---------|-------------------------------|-------|
|--------------------|-------|---------|-------------------------------|-------|

HAEMATOLOGY

MEDI WHEEL FULL BODY HEALTH CHECK UP BELOW 40 MALE**ERYTHROCYTE SEDIMENTATION RATE (ESR),WHOLE BLOOD**

| | | | |
|-------|---|--------|------------|
| E.S.R | 2 | 0 - 14 | mm at 1 hr |
|-------|---|--------|------------|

METHOD : AUTOMATED (PHOTOMETRICAL CAPILLARY STOPPED FLOW KINETIC ANALYSIS)

Interpretation(s)**ERYTHROCYTE SEDIMENTATION RATE (ESR),WHOLE BLOOD-TEST DESCRIPTION :-**

Erythrocyte sedimentation rate (ESR) is a test that indirectly measures the degree of inflammation present in the body. The test actually measures the rate of fall (sedimentation) of erythrocytes in a sample of blood that has been placed into a tall, thin, vertical tube. Results are reported as the millimetres of clear fluid (plasma) that are present at the top portion of the tube after one hour. Nowadays fully automated instruments are available to measure ESR.

ESR is not diagnostic; it is a non-specific test that may be elevated in a number of different conditions. It provides general information about the presence of an inflammatory condition. CRP is superior to ESR because it is more sensitive and reflects a more rapid change.

TEST INTERPRETATION

Increase in: Infections, Vasculitides, Inflammatory arthritis, Renal disease, Anemia, Malignancies and plasma cell dyscrasias, Acute allergy Tissue injury, Pregnancy, Estrogen medication, Aging.

Finding a very accelerated ESR (>100 mm/hour) in patients with ill-defined symptoms directs the physician to search for a systemic disease (Paraproteinemias, Disseminated malignancies, connective tissue disease, severe infections such as bacterial endocarditis).

In pregnancy BRI in first trimester is 0-48 mm/hr(62 if anemic) and in second trimester (0-70 mm /hr(95 if anemic). ESR returns to normal 4th week post partum.

Decreased in: Polycythemia vera, Sickle cell anemia

LIMITATIONS

False elevated ESR : Increased fibrinogen, Drugs(Vitamin A, Dextran etc), Hypercholesterolemia

False Decreased : Poikilocytosis,(SickleCells,spherocytes),Microcytosis, Low fibrinogen, Very high WBC counts, Drugs(Quinine, salicylates)

REFERENCE :

1. Nathan and Oski's Haematology of Infancy and Childhood, 5th edition;2. Paediatric reference intervals. AACC Press, 7th edition. Edited by S. Soldin;3. The reference for the adult reference range is "Practical Haematology by Dacie and Lewis,10th edition.

Dr. Reena Mittal, MD
Senior Consultant
Hematopathologist

Dr. Sushant Chikane
Consultant Pathologist

Page 8 Of 24



View Details



View Report

PERFORMED AT :

SRL Ltd
PRIME SQUARE BUILDING,PLOT NO 1,GAIWADI INDUSTRIAL ESTATE,S.V. ROAD,GOREGAON (W)
Mumbai, 400062
MAHARASHTRA, INDIA
Tel : 9111591115, Fax :
CIN - U74899PB1995PLC045956



Patient Ref. No. 2000011707303



MC-2010

PATIENT NAME : DINESH JHA

REF. DOCTOR : SELF

400089
Mumbai 400089
 ACCESSION NO : **0002WD005640**
 PATIENT ID : DINEM05108827
 CLIENT PATIENT ID:
 ABHA NO :

 AGE/SEX : 34 Years Male
 DRAWN : 04/04/2023 10:28:15
 RECEIVED : 04/04/2023 10:30:05
 REPORTED : 05/04/2023 15:33:27

| Test Report Status | Final | Results | Biological Reference Interval | Units |
|--------------------|-------|---------|-------------------------------|-------|
|--------------------|-------|---------|-------------------------------|-------|

IMMUNOHAEMATOLOGY

MEDI WHEEL FULL BODY HEALTH CHECK UP BELOW 40 MALE

ABO GROUP & RH TYPE, EDTA WHOLE BLOOD

| | |
|--|----------|
| ABO GROUP | O |
| METHOD : HAEMAGGLUTINATION (AUTOMATED) | |
| RH TYPE | POSITIVE |
| METHOD : HAEMAGGLUTINATION (AUTOMATED) | |

Interpretation(s)

ABO GROUP & RH TYPE, EDTA WHOLE BLOOD-

Blood group is identified by antigens and antibodies present in the blood. Antigens are protein molecules found on the surface of red blood cells. Antibodies are found in plasma. To determine blood group, red cells are mixed with different antibody solutions to give A,B,O or AB.

Disclaimer: "Please note, as the results of previous ABO and Rh group (Blood Group) for pregnant women are not available, please check with the patient records for availability of the same."

The test is performed by both forward as well as reverse grouping methods.

Dr. Sushant Chikane
Consultant Pathologist

Page 9 Of 24



View Details



View Report

PERFORMED AT :

SRL Ltd
PRIME SQUARE BUILDING,PLOT NO 1,GAIWADI INDUSTRIAL ESTATE,S.V. ROAD,GOREGAON (W)
Mumbai, 400062
MAHARASHTRA, INDIA
Tel : 9111591115, Fax :
CIN - U74899PB1995PLC045956



Patient Ref. No. 2000011707303



MC-2010

PATIENT NAME : DINESH JHA

REF. DOCTOR : SELF

400089
Mumbai 400089

ACCESSION NO : **0002WD005640**
 PATIENT ID : DINEM05108827
 CLIENT PATIENT ID:
 ABHA NO :

AGE/SEX : 34 Years Male
 DRAWN : 04/04/2023 10:28:15
 RECEIVED : 04/04/2023 10:30:05
 REPORTED : 05/04/2023 15:33:27

| Test Report Status | Final | Results | Biological Reference Interval | Units |
|--------------------|-------|---------|-------------------------------|-------|
|--------------------|-------|---------|-------------------------------|-------|


BIOCHEMISTRY

MEDI WHEEL FULL BODY HEALTH CHECK UP BELOW 40 MALE

GLUCOSE FASTING, FLUORIDE PLASMA

FBS (FASTING BLOOD SUGAR) 98 Normal <100 mg/dL
 Impaired fasting glucose: 100 to 125
 Diabetes mellitus: > = 126 (on more than 1 occasion)
 (ADA guidelines 2021)

METHOD : SPECTROPHOTOMETRY HEXOKINASE



GLYCOSYLATED HEMOGLOBIN (HBA1C), EDTA WHOLE BLOOD

HBA1C 4.6 Non-diabetic Adult < 5.7 %
 Pre-diabetes 5.7 - 6.4
 Diabetes diagnosis: > or = 6.5
 Therapeutic goals: < 7.0
 Action suggested : > 8.0
 (ADA Guideline 2021)

METHOD : ION- EXCHANGE HPLC

S.S. Wadalkar

Dr. Sneha Wadalkar, M.D
 (Reg.no.MMC2012/06/1868)
 Junior Biochemist



View Details



View Report

PERFORMED AT :

SRL Ltd
 PRIME SQUARE BUILDING, PLOT NO 1, GAIWADI INDUSTRIAL ESTATE, S.V. ROAD, GOREGAON (W)
 Mumbai, 400062
 MAHARASHTRA, INDIA
 Tel : 9111591115, Fax :
 CIN - U74899PB1995PLC045956



Patient Ref. No. 2000011707303



MC-2010

PATIENT NAME : DINESH JHA

REF. DOCTOR : SELF

400089
Mumbai 400089

| | |
|------------------------------------|--------------------------------|
| ACCESSION NO : 0002WD005640 | AGE/SEX : 34 Years Male |
| PATIENT ID : DINEM05108827 | DRAWN : 04/04/2023 10:28:15 |
| CLIENT PATIENT ID: | RECEIVED : 04/04/2023 10:30:05 |
| ABHA NO : | REPORTED : 05/04/2023 15:33:27 |

| Test Report Status | Final | Results | Biological Reference Interval | Units |
|--------------------|-------|---------|-------------------------------|-------|
|--------------------|-------|---------|-------------------------------|-------|

| | | | |
|--------------------------------|------|-------|-------|
| ESTIMATED AVERAGE GLUCOSE(EAG) | 85.3 | < 116 | mg/dL |
|--------------------------------|------|-------|-------|

| | | | |
|---------------------------------------|-----|--|-------|
| GLUCOSE, POST-PRANDIAL, PLASMA | | | |
| PPBS(POST PRANDIAL BLOOD SUGAR) | 119 | Normal <140 Impaired glucose tolerance:140 to 199 Diabetes mellitus : > = 200 (on more than 1 occasion) ADA guideline 2021 | mg/dL |

METHOD : SPECTROPHOTOMETRY HEXOKINASE

LIPID PROFILE, SERUM

| | | | |
|--------------------|-----|---|-------|
| CHOLESTEROL, TOTAL | 159 | Desirable : < 200 Borderline : 200 - 239 High : > / = 240 | mg/dL |
|--------------------|-----|---|-------|

METHOD : SPECTROPHOTOMETRY, ENZYMATIC COLORIMETRIC - CHOLETSEROL OXIDASE, ESTERASE, PEROXIDASE

| | | | |
|---------------|-----------------|--|-------|
| TRIGLYCERIDES | 216 High | Normal: < 150 Borderline high: 150 - 199 High: 200 - 499 Very High: >/= 500 | mg/dL |
|---------------|-----------------|--|-------|

METHOD : SPECTROPHOTOMETRY, ENZYMATIC ENDPOINT WITH GLYCEROL BLANK

| | | | |
|-----------------|----|---------------------------------------|-------|
| HDL CHOLESTEROL | 45 | At Risk: < 40 Desirable: > or = 60 | mg/dL |
|-----------------|----|---------------------------------------|-------|

METHOD : SPECTROPHOTOMETRY, HOMOGENEOUS DIRECT ENZYMATIC COLORIMETRIC

| | | | |
|-----------------|----|---|-------|
| CHOLESTEROL LDL | 71 | Optimal : < 100 Near optimal/above optimal : 100-129 Borderline high : 130-159 High : 160-189 Very high : = 190 | mg/dL |
|-----------------|----|---|-------|

METHOD : CALCULATED PARAMETER

| | | | |
|---------------------|-----|---|-------|
| NON HDL CHOLESTEROL | 114 | Desirable : < 130 Above Desirable : 130 -159 Borderline High : 160 - 189 High : 190 - 219 Very high : > / = 220 | mg/dL |
|---------------------|-----|---|-------|

METHOD : CALCULATED PARAMETER

| | | | |
|------------------------------|------------------|-------------|-------|
| VERY LOW DENSITY LIPOPROTEIN | 43.0 High | < or = 30.0 | mg/dL |
|------------------------------|------------------|-------------|-------|

METHOD : CALCULATED PARAMETER

S.S. Wadalkar

Dr. Sneha Wadalkar, M.D
(Reg.no.MMC2012/06/1868)
Junior Biochemist



[View Details](#) [View Report](#)

PERFORMED AT :

SRL Ltd
PRIME SQUARE BUILDING,PLOT NO 1,GAIWADI INDUSTRIAL ESTATE,S.V. ROAD,GOREGAON (W)
Mumbai, 400062
MAHARASHTRA, INDIA
Tel : 9111591115, Fax :
CIN - U74899PB1995PLC045956



Patient Ref. No. 2000011707303



MC-2010

PATIENT NAME : DINESH JHA

REF. DOCTOR : SELF

400089
Mumbai 400089

ACCESSION NO : **0002WD005640**
PATIENT ID : DINEM05108827
CLIENT PATIENT ID:
ABHA NO :

AGE/SEX : 34 Years Male
DRAWN : 04/04/2023 10:28:15
RECEIVED : 04/04/2023 10:30:05
REPORTED : 05/04/2023 15:33:27

| Test Report Status | Final | Results | Biological Reference Interval | Units |
|--------------------|-------|---------|-------------------------------|-------|
|--------------------|-------|---------|-------------------------------|-------|

CHOL/HDL RATIO 3.5
Low Risk : 3.3 - 4.4
Average Risk : 4.5 - 7.0
Moderate Risk : 7.1 - 11.0
High Risk : > 11.0

METHOD : CALCULATED PARAMETER

LDL/HDL RATIO 2.1
Desirable/Low Risk : 0.5 - 3.0
Borderline/Moderate Risk : 3.1 - 6.0
High Risk : > 6.0

METHOD : CALCULATED PARAMETER

Interpretation(s)

Serum lipid profile is measured for cardiovascular risk prediction. Lipid Association of India recommends LDL-C as primary target and Non HDL-C as co-primary treatment target.

Risk Stratification for ASCVD (Atherosclerotic cardiovascular disease) by Lipid Association of India

| Risk Category | |
|---|--|
| Extreme risk group | A. CAD with > 1 feature of high risk group |
| | B. CAD with > 1 feature of Very high risk group or recurrent ACS (within 1 year) despite LDL-C < or = 50 mg/dl or polyvascular disease |
| Very High Risk | 1. Established ASCVD 2. Diabetes with 2 major risk factors or evidence of end organ damage 3. Familial Homozygous Hypercholesterolemia |
| High Risk | 1. Three major ASCVD risk factors. 2. Diabetes with 1 major risk factor or no evidence of end organ damage. 3. CKD stage 3B or 4. 4. LDL >190 mg/dl 5. Extreme of a single risk factor. 6. Coronary Artery Calcium - CAC >300 AU. 7. Lipoprotein a >= 50mg/dl 8. Non stenotic carotid plaque |
| Moderate Risk | 2 major ASCVD risk factors |
| Low Risk | 0-1 major ASCVD risk factors |
| Major ASCVD (Atherosclerotic cardiovascular disease) Risk Factors | |
| 1. Age > or = 45 years in males and > or = 55 years in females | 3. Current Cigarette smoking or tobacco use |
| 2. Family history of premature ASCVD | 4. High blood pressure |
| 5. Low HDL | |

Newer treatment goals and statin initiation thresholds based on the risk categories proposed by LAI in 2020.

| Risk Group | Treatment Goals | | Consider Drug Therapy | |
|-------------------------------|--------------------------------|-------------------------------|-----------------------|-----------------|
| | LDL-C (mg/dl) | Non-HDL (mg/dl) | LDL-C (mg/dl) | Non-HDL (mg/dl) |
| Extreme Risk Group Category A | <50 (Optional goal < OR = 30) | < 80 (Optional goal <OR = 60) | >OR = 50 | >OR = 80 |
| Extreme Risk Group Category B | <OR = 30 | <OR = 60 | > 30 | >60 |
| Very High Risk | <50 | <80 | >OR= 50 | >OR= 80 |
| High Risk | <70 | <100 | >OR= 70 | >OR= 100 |
| Moderate Risk | <100 | <130 | >OR= 100 | >OR= 130 |
| Low Risk | <100 | <130 | >OR= 130* | >OR= 160 |

*After an adequate non-pharmacological intervention for at least 3 months.

S.S. Wadalkar

Dr. Sneha Wadalkar, M.D
(Reg.no.MMC2012/06/1868)
Junior Biochemist



View Details



View Report

PERFORMED AT :

SRL Ltd
PRIME SQUARE BUILDING,PLOT NO 1,GAIWADI INDUSTRIAL ESTATE,S.V. ROAD,GOREGAON (W)
Mumbai, 400062
MAHARASHTRA, INDIA
Tel : 9111591115, Fax :
CIN - U74899PB1995PLC045956



Patient Ref. No. 2000011707303



MC-2010

PATIENT NAME : DINESH JHA

REF. DOCTOR : SELF

400089
Mumbai 400089

ACCESSION NO : **0002WD005640**
PATIENT ID : DINEM05108827
CLIENT PATIENT ID:
ABHA NO :

AGE/SEX : 34 Years Male
DRAWN : 04/04/2023 10:28:15
RECEIVED : 04/04/2023 10:30:05
REPORTED : 05/04/2023 15:33:27

| Test Report Status | Final | Results | Biological Reference Interval | Units |
|--------------------|-------|---------|-------------------------------|-------|
|--------------------|-------|---------|-------------------------------|-------|

References: Management of Dyslipidaemia for the Prevention of Stroke: Clinical Practice Recommendations from the Lipid Association of India. Current Vascular Pharmacology, 2022, 20, 134-155.

LIVER FUNCTION PROFILE, SERUM

| | | | |
|---|------------------|-------------|-------|
| BILIRUBIN, TOTAL METHOD : SPECTROPHOTOMETRY, COLORIMETRIC -DIAZO METHOD | 0.62 | Upto 1.2 | mg/dL |
| BILIRUBIN, DIRECT METHOD : SPECTROPHOTOMETRY, JENDRASSIK & GROFF - DIAZOTIZATION | 0.35 High | < or = 0.3 | mg/dL |
| BILIRUBIN, INDIRECT METHOD : CALCULATED PARAMETER | 0.27 | 0.0 - 0.9 | mg/dL |
| TOTAL PROTEIN METHOD : SPECTROPHOTOMETRY, COLORIMETRIC -BIURET, REAGENT BLANK, SERUM BLANK | 7.3 | 6.0 - 8.0 | g/dL |
| ALBUMIN METHOD : SPECTROPHOTOMETRY, BROMOCRESOL GREEN(BCG) - DYE BINDING | 4.9 | 3.97 - 4.94 | g/dL |
| GLOBULIN METHOD : CALCULATED PARAMETER | 2.4 | 2.0 - 3.5 | g/dL |
| ALBUMIN/GLOBULIN RATIO METHOD : CALCULATED PARAMETER | 2.0 | 1.0 - 2.1 | RATIO |
| ASPARTATE AMINOTRANSFERASE(AST/SGOT) METHOD : SPECTROPHOTOMETRY, WITHOUT PYRIDOXAL PHOSPHATE ACTIVATION(P5P) - IFCC | 31 | Upto 40 | U/L |
| ALANINE AMINOTRANSFERASE (ALT/SGPT) METHOD : SPECTROPHOTOMETRY, WITHOUT PYRIDOXAL PHOSPHATE ACTIVATION(P5P) - IFCC | 48 High | Upto 41 | U/L |
| ALKALINE PHOSPHATASE METHOD : SPECTROPHOTOMETRY, PNPP, AMP BUFFER - IFCC | 65 | 40 - 129 | U/L |
| GAMMA GLUTAMYL TRANSFERASE (GGT) METHOD : SPECTROPHOTOMETRY, ENZYMATIC COLORIMETRIC - G-GLUTAMYL-CARBOXY-NITROANILIDE - IFCC | 72 High | < 60 | U/L |
| LACTATE DEHYDROGENASE METHOD : SPECTROPHOTOMETRY, LACTATE TO PYRUVATE - UV-IFCC | 144 | < 232 | U/L |

BLOOD UREA NITROGEN (BUN), SERUM

| | | | |
|---|---|--------|-------|
| BLOOD UREA NITROGEN METHOD : SPECTROPHOTOMETRY, UREASE -COLORIMETRIC | 8 | 6 - 20 | mg/dL |
|---|---|--------|-------|

S.S. Wadalkar

Dr. Sneha Wadalkar, M.D
(Reg.no.MMC2012/06/1868)
Junior Biochemist



View Details



View Report

PERFORMED AT :

SRL Ltd
PRIME SQUARE BUILDING,PLOT NO 1,GAIWADI INDUSTRIAL ESTATE,S.V. ROAD,GOREGAON (W)
Mumbai, 400062
MAHARASHTRA, INDIA
Tel : 9111591115, Fax :
CIN - U74899PB1995PLC045956



Patient Ref. No. 2000011707303



MC-2010

PATIENT NAME : DINESH JHA


REF. DOCTOR : SELF

400089
Mumbai 400089

ACCESSION NO : **0002WD005640**
PATIENT ID : DINEM05108827
CLIENT PATIENT ID:
ABHA NO :

AGE/SEX : 34 Years Male
DRAWN : 04/04/2023 10:28:15
RECEIVED : 04/04/2023 10:30:05
REPORTED : 05/04/2023 15:33:27

| Test Report Status | Final | Results | Biological Reference Interval | Units |
|--------------------|-------|---------|-------------------------------|-------|
|--------------------|-------|---------|-------------------------------|-------|



CREATININE, SERUM

CREATININE 0.98 0.90 - 1.30 mg/dL
METHOD : SPECTROPHOTOMETRY, JAFFE'S ALKALINE PICRATE KINETIC - RATE BLANKED - IFCC-IDMS STANDARDIZED

S.S. Wadalkar

Dr. Sneha Wadalkar, M.D
(Reg.no.MMC2012/06/1868)
Junior Biochemist



View Details



View Report

PERFORMED AT :

SRL Ltd
PRIME SQUARE BUILDING,PLOT NO 1,GAIWADI INDUSTRIAL ESTATE,S.V. ROAD,GOREGAON (W)
Mumbai, 400062
MAHARASHTRA, INDIA
Tel : 9111591115, Fax :
CIN - U74899PB1995PLC045956



Patient Ref. No. 2000011707303



MC-2010

PATIENT NAME : DINESH JHA


REF. DOCTOR : SELF

400089
Mumbai 400089

ACCESSION NO : **0002WD005640**
PATIENT ID : DINEM05108827
CLIENT PATIENT ID:
ABHA NO :

AGE/SEX : 34 Years Male
DRAWN : 04/04/2023 10:28:15
RECEIVED : 04/04/2023 10:30:05
REPORTED : 05/04/2023 15:33:27

| Test Report Status | Final | Results | Biological Reference Interval | Units |
|--------------------|-------|---------|-------------------------------|-------|
|--------------------|-------|---------|-------------------------------|-------|



BUN/CREAT RATIO

BUN/CREAT RATIO 8.10 8 - 15
METHOD : CALCULATED PARAMETER

URIC ACID, SERUM

URIC ACID 6.5 3.4 - 7.0 mg/dL
METHOD : SPECTROPHOTOMETRY, ENZYMATIC COLORIMETRIC- URICASE

TOTAL PROTEIN, SERUM

TOTAL PROTEIN 7.3 6.0 - 8.0 g/dL
METHOD : SPECTROPHOTOMETRY, COLORIMETRIC -BIURET, REAGENT BLANK, SERUM BLANK

ALBUMIN, SERUM

ALBUMIN 4.9 3.97 - 4.94 g/dL
METHOD : SPECTROPHOTOMETRY, BROMOCRESOL GREEN(BCG) - DYE BINDING

GLOBULIN

GLOBULIN 2.4 2.0 - 3.5 g/dL
METHOD : CALCULATED PARAMETER

S.S. Wadalkar

Dr. Sneha Wadalkar, M.D
(Reg.no.MMC2012/06/1868)
Junior Biochemist



View Details



View Report

PERFORMED AT :

SRL Ltd
PRIME SQUARE BUILDING,PLOT NO 1,GAIWADI INDUSTRIAL ESTATE,S.V. ROAD,GOREGAON (W)
Mumbai, 400062
MAHARASHTRA, INDIA
Tel : 9111591115, Fax :
CIN - U74899PB1995PLC045956



Patient Ref. No. 2000011707303



MC-2010

PATIENT NAME : DINESH JHA

REF. DOCTOR : SELF

400089
Mumbai 400089

ACCESSION NO : **0002WD005640**
PATIENT ID : DINEM05108827
CLIENT PATIENT ID:
ABHA NO :

AGE/SEX : 34 Years Male
DRAWN : 04/04/2023 10:28:15
RECEIVED : 04/04/2023 10:30:05
REPORTED : 05/04/2023 15:33:27

| Test Report Status | Final | Results | Biological Reference Interval | Units |
|--------------------|-------|---------|-------------------------------|-------|
|--------------------|-------|---------|-------------------------------|-------|

ELECTROLYTES (NA/K/CL), SERUM

| | | | |
|---|------------------|-----------|--------|
| SODIUM, SERUM METHOD : ISE INDIRECT | 140 | 136 - 145 | mmol/L |
| POTASSIUM, SERUM METHOD : ISE INDIRECT | 5.20 High | 3.5 - 5.1 | mmol/L |
| CHLORIDE, SERUM METHOD : ISE INDIRECT | 105 | 98 - 106 | mmol/L |

Interpretation(s)

| Sodium | Potassium | Chloride |
|---|--|---|
| Decreased in: CCF, cirrhosis, vomiting, diarrhea, excessive sweating, salt-losing nephropathy, adrenal insufficiency, nephrotic syndrome, water intoxication, SIADH. Drugs: thiazides, diuretics, ACE inhibitors, chlorpropamide, carbamazepine, antidepressants (SSRI), antipsychotics. | Decreased in: Low potassium intake, prolonged vomiting or diarrhea, RTA types I and II, hyperaldosteronism, Cushing's syndrome, osmotic diuresis (e.g., hyperglycemia), alkalosis, familial periodic paralysis, trauma (transient). Drugs: Adrenergic agents, diuretics. | Decreased in: Vomiting, diarrhea, renal failure combined with salt deprivation, over-treatment with diuretics, chronic respiratory acidosis, diabetic ketoacidosis, excessive sweating, SIADH, salt-losing nephropathy, porphyria, expansion of extracellular fluid volume, adrenal insufficiency, hyperaldosteronism, metabolic alkalosis. Drugs: chronic laxative, corticosteroids, diuretics. |
| Increased in: Dehydration (excessive sweating, severe vomiting or diarrhea), diabetes mellitus, diabetes insipidus, hyperaldosteronism, inadequate water intake. Drugs: steroids, licorice, oral contraceptives. | Increased in: Massive hemolysis, severe tissue damage, rhabdomyolysis, acidosis, dehydration, renal failure, Addison's disease, RTA type IV, hyperkalemic familial periodic paralysis. Drugs: potassium salts, potassium-sparing diuretics, NSAIDs, beta-blockers, ACE inhibitors, high-dose trimethoprim-sulfamethoxazole. | Increased in: Renal failure, nephrotic syndrome, RTA, dehydration, overtreatment with saline, hyperparathyroidism, diabetes insipidus, metabolic acidosis from diarrhea (Loss of HCO ₃ ⁻), respiratory alkalosis, hyperadrenocorticism. Drugs: acetazolamide, androgens, hydrochlorothiazide, salicylates. |
| Interferences: Severe lipemia or hyperproteinemia, if sodium analysis involves a dilution step can cause spurious results. The serum sodium falls about 1.6 mEq/L for each 100 mg/dL increase in blood glucose. | Interferences: Hemolysis of sample, delayed separation of serum, prolonged fist clenching during blood drawing, and prolonged tourniquet placement. Very high WBC/PLT counts may cause spurious. Plasma potassium levels are normal. | Interferences: Test is helpful in assessing normal and increased anion gap metabolic acidosis and in distinguishing hypercalcemia due to hyperparathyroidism (high serum chloride) from that due to malignancy (Normal serum chloride) |

Interpretation(s)

GLUCOSE FASTING, FLUORIDE PLASMA-TEST DESCRIPTION

Normally, the glucose concentration in extracellular fluid is closely regulated so that a source of energy is readily available to tissues and so that no glucose is excreted in the urine.

Increased in: Diabetes mellitus, Cushing's syndrome (10 - 15%), chronic pancreatitis (30%). Drugs: corticosteroids, phenytoin, estrogen, thiazides.

Decreased in: Pancreatic islet cell disease with increased insulin, insulinoma, adrenocortical insufficiency, hypopituitarism, diffuse liver disease, malignancy (adrenocortical, stomach, fibrosarcoma), infant of a diabetic mother, enzyme deficiency diseases (e.g. galactosemia), Drugs-insulin, ethanol, propranolol; sulfonyleureas, tolbutamide, and other oral hypoglycemic agents.

NOTE: While random serum glucose levels correlate with home glucose monitoring results (weekly mean capillary glucose values), there is wide fluctuation within

S.S. Wadalkar

Dr. Sneha Wadalkar, M.D
(Reg.no.MMC2012/06/1868)
Junior Biochemist



View Details



View Report

PERFORMED AT :

SRL Ltd
PRIME SQUARE BUILDING, PLOT NO 1, GAIWADI INDUSTRIAL ESTATE, S.V. ROAD, GOREGAON (W)
Mumbai, 400062
MAHARASHTRA, INDIA
Tel : 9111591115, Fax :
CIN - U74899PB1995PLC045956



Patient Ref. No. 2000011707303



MC-2010

PATIENT NAME : DINESH JHA

REF. DOCTOR : SELF

| | | |
|-------------------------|------------------------------------|--------------------------------|
| 400089 Mumbai 400089 | ACCESSION NO : 0002WD005640 | AGE/SEX : 34 Years Male |
| | PATIENT ID : DINEM05108827 | DRAWN : 04/04/2023 10:28:15 |
| | CLIENT PATIENT ID : | RECEIVED : 04/04/2023 10:30:05 |
| | ABHA NO : | REPORTED : 05/04/2023 15:33:27 |

| Test Report Status | Final | Results | Biological Reference Interval | Units |
|--------------------|-------|---------|-------------------------------|-------|
|--------------------|-------|---------|-------------------------------|-------|

individuals. Thus, glycosylated hemoglobin (HbA1c) levels are favored to monitor glycemic control. High fasting glucose level in comparison to post prandial glucose level may be seen due to effect of Oral Hypoglycaemics & Insulin treatment, Renal Glycosuria, Glycaemic index & response to food consumed, Alimentary Hypoglycemia, Increased insulin response & sensitivity etc. GLYCOSYLATED HEMOGLOBIN (HbA1C), EDTA WHOLE BLOOD - **Used For:**

- Evaluating the long-term control of blood glucose concentrations in diabetic patients.
- Diagnosing diabetes.
- Identifying patients at increased risk for diabetes (prediabetes).
- The ADA recommends measurement of HbA1c (typically 3-4 times per year for type 1 and poorly controlled type 2 diabetic patients, and 2 times per year for well-controlled type 2 diabetic patients) to determine whether a patient's metabolic control has remained continuously within the target range.
- eAG (Estimated average glucose) converts percentage HbA1c to mg/dl, to compare blood glucose levels.
- eAG gives an evaluation of blood glucose levels for the last couple of months.
- eAG is calculated as $eAG (mg/dl) = 28.7 * HbA1c - 46.7$

HbA1c Estimation can get affected due to :

- Shortened Erythrocyte survival : Any condition that shortens erythrocyte survival or decreases mean erythrocyte age (e.g. recovery from acute blood loss, hemolytic anemia) will falsely lower HbA1c test results. Fructosamine is recommended in these patients which indicates diabetes control over 15 days.
- Vitamin C & E are reported to falsely lower test results. (possibly by inhibiting glycation of hemoglobin).
- Iron deficiency anemia is reported to increase test results. Hypertriglyceridemia, uremia, hyperbilirubinemia, chronic alcoholism, chronic ingestion of salicylates & opiates addition are reported to interfere with some assay methods, falsely increasing results.
- Interference of hemoglobinopathies in HbA1c estimation is seen in

- Homozygous hemoglobinopathy. Fructosamine is recommended for testing of HbA1c.
- Heterozygous state detected (D10 is corrected for HbS & HbC trait.)
- HbF > 25% on alternate platform (Boronate affinity chromatography) is recommended for testing of HbA1c. Abnormal Hemoglobin electrophoresis (HPLC method) is recommended for detecting a hemoglobinopathy

GLUCOSE, POST-PRANDIAL, PLASMA - High fasting glucose level in comparison to post prandial glucose level may be seen due to effect of Oral Hypoglycaemics & Insulin treatment, Renal Glycosuria, Glycaemic index & response to food consumed, Alimentary Hypoglycemia, Increased insulin response & sensitivity etc. Additional test HbA1c LIVER FUNCTION PROFILE, SERUM-

Bilirubin is a yellowish pigment found in bile and is a breakdown product of normal heme catabolism. Bilirubin is excreted in bile and urine, and elevated levels may give yellow discoloration in jaundice. **Elevated levels** results from increased bilirubin production (eg, hemolysis and ineffective erythropoiesis), decreased bilirubin excretion (eg, obstruction and hepatitis), and abnormal bilirubin metabolism (eg, hereditary and neonatal jaundice). Conjugated (direct) bilirubin is elevated more than unconjugated (indirect) bilirubin in Viral hepatitis, Drug reactions, Alcoholic liver disease. Conjugated (direct) bilirubin is also elevated more than unconjugated (indirect) bilirubin when there is some kind of blockage of the bile ducts like in Gallstones getting into the bile ducts, tumors & scarring of the bile ducts. Increased unconjugated (indirect) bilirubin may be a result of Hemolytic or pernicious anemia, Transfusion reaction & a common metabolic condition termed Gilbert syndrome, due to low levels of the enzyme that attaches sugar molecules to bilirubin.

AST is an enzyme found in various parts of the body. AST is found in the liver, heart, skeletal muscle, kidneys, brain, and red blood cells, and it is commonly measured clinically as a marker for liver health. AST levels increase during chronic viral hepatitis, blockage of the bile duct, cirrhosis of the liver, liver cancer, kidney failure, hemolytic anemia, pancreatitis, hemochromatosis. AST levels may also increase after a heart attack or strenuous activity. ALT test measures the amount of this enzyme in the blood. ALT is found mainly in the liver, but also in smaller amounts in the kidneys, heart, muscles, and pancreas. It is commonly measured as a part of a diagnostic evaluation of hepatocellular injury, to determine liver health. AST levels increase during acute hepatitis, sometimes due to a viral infection, ischemia to the liver, chronic hepatitis, obstruction of bile ducts, cirrhosis.

ALP is a protein found in almost all body tissues. Tissues with higher amounts of ALP include the liver, bile ducts and bone. Elevated ALP levels are seen in Biliary obstruction, Osteoblastic bone tumors, osteomalacia, hepatitis, Hyperparathyroidism, Leukemia, Lymphoma, Paget's disease, Rickets, Sarcoidosis etc. Lower-than-normal ALP levels seen in Hypophosphatasia, Malnutrition, Protein deficiency, Wilson's disease.

GGT is an enzyme found in cell membranes of many tissues mainly in the liver, kidney and pancreas. It is also found in other tissues including intestine, spleen, heart, brain and seminal vesicles. The highest concentration is in the kidney, but the liver is considered the source of normal enzyme activity. Serum GGT has been widely used as an index of liver dysfunction. Elevated serum GGT activity can be found in diseases of the liver, biliary system and pancreas. Conditions that increase serum GGT are obstructive liver disease, high alcohol consumption and use of enzyme-inducing drugs etc.

Total Protein also known as total protein, is a biochemical test for measuring the total amount of protein in serum. Protein in the plasma is made up of albumin and globulin. Higher-than-normal levels may be due to: Chronic inflammation or infection, including HIV and hepatitis B or C, Multiple myeloma, Waldenstrom's disease. Lower-than-normal levels may be due to: Agammaglobulinemia, Bleeding (hemorrhage), Burns, Glomerulonephritis, Liver disease, Malabsorption, Malnutrition, Nephrotic syndrome, Protein-losing enteropathy etc.

Albumin is the most abundant protein in human blood plasma. It is produced in the liver. Albumin constitutes about half of the blood serum protein. Low blood albumin levels (hypoalbuminemia) can be caused by: Liver disease like cirrhosis of the liver, nephrotic syndrome, protein-losing enteropathy, Burns, hemodilution, increased vascular permeability or decreased lymphatic clearance, malnutrition and wasting etc

BLOOD UREA NITROGEN (BUN), SERUM - Causes of Increased levels include Pre renal (High protein diet, Increased protein catabolism, GI haemorrhage, Cortisol, Dehydration, CHF Renal), Renal Failure, Post Renal (Maligancy, Nephrolithiasis, Prostatism)

Causes of decreased level include Liver disease, SIADH.

CREATININE, SERUM - Higher than normal level may be due to:

- Blockage in the urinary tract, Kidney problems, such as kidney damage or failure, infection, or reduced blood flow, Loss of body fluid (dehydration), Muscle problems, such as breakdown of muscle fibers, Problems during pregnancy, such as seizures (eclampsia)), or high blood pressure caused by pregnancy (preeclampsia)

Lower than normal level may be due to:

S.S. Wadalkar

Dr. Sneha Wadalkar, M.D
(Reg. no. MMC2012/06/1868)
Junior Biochemist



View Details



View Report

PERFORMED AT :

SRL Ltd
PRIME SQUARE BUILDING, PLOT NO 1, GAIWADI INDUSTRIAL ESTATE, S.V. ROAD, GOREGAON (W)
Mumbai, 400062
MAHARASHTRA, INDIA
Tel : 9111591115, Fax :
CIN - U74899PB1995PLC045956



Patient Ref. No. 2000011707303



MC-2010

PATIENT NAME : DINESH JHA

REF. DOCTOR : SELF

400089
Mumbai 400089

ACCESSION NO : **0002WD005640**
 PATIENT ID : DINEM05108827
 CLIENT PATIENT ID:
 ABHA NO :

AGE/SEX : 34 Years Male
 DRAWN : 04/04/2023 10:28:15
 RECEIVED : 04/04/2023 10:30:05
 REPORTED : 05/04/2023 15:33:27

| Test Report Status | Final | Results | Biological Reference Interval | Units |
|--------------------|-------|---------|-------------------------------|-------|
|--------------------|-------|---------|-------------------------------|-------|

• Myasthenia Gravis, Muscuophy
 URIC ACID, SERUM-**Causes of Increased levels**:-Dietary(High Protein Intake,Prolonged Fasting,Rapid weight loss),Gout,Lesch nyhan syndrome,Type 2 DM,Metabolic syndrome **Causes of decreased levels**-Low Zinc intake,OCP,Multiple Sclerosis
 TOTAL PROTEIN, SERUM-is a biochemical test for measuring the total amount of protein in serum.Protein in the plasma is made up of albumin and globulin.
Higher-than-normal levels may be due to: Chronic inflammation or infection, including HIV and hepatitis B or C, Multiple myeloma,Waldenstroms disease.
Lower-than-normal levels may be due to: Agammaglobulinemia, Bleeding (hemorrhage),Burns,Glomerulonephritis, Liver disease, Malabsorption, Malnutrition, Nephrotic syndrome,Protein-losing enteropathy etc.
 ALBUMIN, SERUM-
 Human serum albumin is the most abundant protein in human blood plasma. It is produced in the liver. Albumin constitutes about half of the blood serum protein. **Low blood albumin levels (hypoalbuminemia) can be caused by:** Liver disease like cirrhosis of the liver, nephrotic syndrome, protein-losing enteropathy, Burns, hemodilution, increased vascular permeability or decreased lymphatic clearance,malnutrition and wasting etc.

S.S.Wadalkar

Dr. Sneha Wadalkar, M.D
 (Reg.no.MMC2012/06/1868)
 Junior Biochemist



View Details



View Report

PERFORMED AT :

SRL Ltd
 PRIME SQUARE BUILDING,PLOT NO 1,GAIWADI INDUSTRIAL ESTATE,S.V. ROAD,GOREGAON (W)
 Mumbai, 400062
 MAHARASHTRA, INDIA
 Tel : 9111591115, Fax :
 CIN - U74899PB1995PLC045956



Patient Ref. No. 2000011707303



MC-2010

PATIENT NAME : DINESH JHA

REF. DOCTOR : SELF

400089
Mumbai 400089

ACCESSION NO : **0002WD005640**
PATIENT ID : DINEM05108827
CLIENT PATIENT ID:
ABHA NO :

AGE/SEX : 34 Years Male
DRAWN : 04/04/2023 10:28:15
RECEIVED : 04/04/2023 10:30:05
REPORTED : 05/04/2023 15:33:27

| Test Report Status | Final | Results | Biological Reference Interval | Units |
|--------------------|-------|---------|-------------------------------|-------|
|--------------------|-------|---------|-------------------------------|-------|

CLINICAL PATH - URINALYSIS

MEDI WHEEL FULL BODY HEALTH CHECK UP BELOW 40 MALE

PHYSICAL EXAMINATION, URINE

COLOR PALE YELLOW
APPEARANCE CLEAR

CHEMICAL EXAMINATION, URINE

| | | |
|--------------------|--------------|---------------|
| PH | 7.0 | 5.00 - 7.50 |
| SPECIFIC GRAVITY | 1.015 | 1.010 - 1.030 |
| PROTEIN | NOT DETECTED | NOT DETECTED |
| GLUCOSE | NOT DETECTED | NOT DETECTED |
| KETONES | NOT DETECTED | NOT DETECTED |
| BLOOD | NOT DETECTED | NOT DETECTED |
| BILIRUBIN | NOT DETECTED | NOT DETECTED |
| UROBILINOGEN | NOT DETECTED | |
| NITRITE | NOT DETECTED | NOT DETECTED |
| LEUKOCYTE ESTERASE | NOT DETECTED | NOT DETECTED |

MICROSCOPIC EXAMINATION, URINE

| | | | |
|------------------|--------------|--------------|------|
| RED BLOOD CELLS | NOT DETECTED | NOT DETECTED | /HPF |
| PUS CELL (WBC'S) | 1-2 | 0-5 | /HPF |
| EPITHELIAL CELLS | 0-1 | 0-5 | /HPF |
| CASTS | NOT DETECTED | | |
| CRYSTALS | NOT DETECTED | | |
| BACTERIA | NOT DETECTED | NOT DETECTED | |
| YEAST | NOT DETECTED | NOT DETECTED | |

METHOD : URINE ROUTINE & MICROSCOPY EXAMINATION BY INTEGRATED AUTOMATED SYSTEM

Interpretation(s)

The following table describes the probable conditions, in which the analytes are present in urine

| Presence of | Conditions |
|-------------------------|---|
| Proteins | Inflammation or immune illnesses |
| Pus (White Blood Cells) | Urinary tract infection, urinary tract or kidney stone, tumors or any kind of kidney impairment |

S.S. Wadalkar

Dr. Sneha Wadalkar, M.D
(Reg.no.MMC2012/06/1868)
Junior Biochemist



View Details



View Report

PERFORMED AT :

SRL Ltd
PRIME SQUARE BUILDING,PLOT NO 1,GAIWADI INDUSTRIAL ESTATE,S.V. ROAD,GOREGAON (W)
Mumbai, 400062
MAHARASHTRA, INDIA
Tel : 9111591115, Fax :
CIN - U74899PB1995PLC045956



Patient Ref. No. 2000011707303



MC-2010

PATIENT NAME : DINESH JHA

REF. DOCTOR : SELF

400089
Mumbai 400089
 ACCESSION NO : **0002WD005640**
 PATIENT ID : DINEM05108827
 CLIENT PATIENT ID:
 ABHA NO :

 AGE/SEX : 34 Years Male
 DRAWN : 04/04/2023 10:28:15
 RECEIVED : 04/04/2023 10:30:05
 REPORTED : 05/04/2023 15:33:27

| | | | | |
|--------------------|--------------|---------|-------------------------------|-------|
| Test Report Status | Final | Results | Biological Reference Interval | Units |
|--------------------|--------------|---------|-------------------------------|-------|

CLINICAL PATH - STOOL ANALYSIS

MEDI WHEEL FULL BODY HEALTH CHECK UP BELOW 40 MALE

MICROSCOPIC EXAMINATION,STOOL

REMARK SAMPLE NOT RECEIVED

Interpretation(s)

Stool routine analysis is only a screening test for disorders of gastrointestinal tract like infection, malabsorption, etc. The following table describes the probable conditions, in which the analytes are present in stool.

| PRESENCE OF | CONDITION |
|-------------------------------|--|
| Pus cells | Pus in the stool is an indication of infection |
| Red Blood cells | Parasitic or bacterial infection or an inflammatory bowel condition such as ulcerative colitis |
| Parasites | Infection of the digestive system. Stool examination for ova and parasite detects presence of parasitic infestation of gastrointestinal tract. Various forms of parasite that can be detected include cyst, trophozoite and larvae. One negative result does not rule out the possibility of parasitic infestation. Intermittent shedding of parasites warrants examinations of multiple specimens tested on consecutive days. Stool specimens for parasitic examination should be collected before initiation of antidiarrheal therapy or antiparasitic therapy. This test does not detect presence of opportunistic parasites like Cyclospora, Cryptosporidia and Isospora species. Examination of Ova and Parasite has been carried out by direct and concentration techniques. |
| Mucus | Mucus is a protective layer that lubricates, protects & reduces damage due to bacteria or viruses. |
| Charcot-Leyden crystal | Parasitic diseases. |
| Ova & cyst | Ova & cyst indicate parasitic infestation of intestine. |
| Frank blood | Bleeding in the rectum or colon. |
| Occult blood | Occult blood indicates upper GI bleeding. |
| Macrophages | Macrophages in stool are an indication of infection as they are protective cells. |
| Epithelial cells | Epithelial cells that normally line the body surface and internal organs show up in stool when there is inflammation or infection. |
| Fat | Increased fat in stool maybe seen in conditions like diarrhoea or malabsorption. |
| pH | Normal stool pH is slightly acidic to neutral. Breast-fed babies generally have an acidic stool. |

ADDITIONAL STOOL TESTS :

- Stool Culture**:- This test is done to find cause of GI infection, make decision about best treatment for GI infection & to find out if treatment for GI infection worked.
- Fecal Calprotectin**: It is a marker of intestinal inflammation. This test is done to differentiate Inflammatory Bowel Disease (IBD) from Irritable Bowel Syndrome (IBS).

Dr. Ekta Patil, MD
(Reg.No. MMC2008/04/1142)
Senior Microbiologist

Page 21 Of 24



View Details



View Report

PERFORMED AT :

SRL Ltd
PRIME SQUARE BUILDING, PLOT NO 1, GAIWADI INDUSTRIAL ESTATE, S.V. ROAD, GOREGAON (W)
Mumbai, 400062
MAHARASHTRA, INDIA
Tel : 9111591115, Fax :
CIN - U74899PB1995PLC045956



Patient Ref. No. 2000011707303



MC-2010

PATIENT NAME : DINESH JHA

REF. DOCTOR : SELF

400089
Mumbai 400089
 ACCESSION NO : **0002WD005640**
 PATIENT ID : DINEM05108827
 CLIENT PATIENT ID:
 ABHA NO :

 AGE/SEX : 34 Years Male
 DRAWN : 04/04/2023 10:28:15
 RECEIVED : 04/04/2023 10:30:05
 REPORTED : 05/04/2023 15:33:27

| Test Report Status | Final | Results | Biological Reference Interval | Units |
|--------------------|-------|---------|-------------------------------|-------|
|--------------------|-------|---------|-------------------------------|-------|

- Fecal Occult Blood Test(FOBT):** This test is done to screen for colon cancer & to evaluate possible cause of unexplained anaemia.
- Clostridium Difficile Toxin Assay:** This test is strongly recommended in healthcare associated bloody or waterydiarrhoea, due to overuse of broad spectrum antibiotics which alter the normal GI flora.
- Biofire (Film Array) GI PANEL:** In patients of Diarrhoea, Dysentery, Rice watery Stool, FDA approved, Biofire Film Array Test,(Real Time Multiplex PCR) is strongly recommended as it identifies organisms, bacteria,fungi,virus ,parasite and other opportunistic pathogens, Vibrio cholera infections only in 3 hours. Sensitivity 96% & Specificity 99%.
- Rota Virus Immunoassay:** This test is recommended in severe gastroenteritis in infants & children associated with watery diarrhoea, vomiting& abdominal cramps. Adults are also affected. It is highly contagious in nature.

Dr. Ekta Patil,MD
(Reg.No. MMC2008/04/1142)
Senior Microbiologist

Page 22 Of 24



View Details



View Report

PERFORMED AT :

SRL Ltd
PRIME SQUARE BUILDING,PLOT NO 1,GAIWADI INDUSTRIAL ESTATE,S.V. ROAD,GOREGAON (W)
Mumbai, 400062
MAHARASHTRA, INDIA
Tel : 9111591115, Fax :
CIN - U74899PB1995PLC045956



Patient Ref. No. 2000011707303



MC-2010

PATIENT NAME : DINESH JHA

REF. DOCTOR : SELF

400089
Mumbai 400089

ACCESSION NO : **0002WD005640**
PATIENT ID : DINEM05108827
CLIENT PATIENT ID:
ABHA NO :

AGE/SEX : 34 Years Male
DRAWN : 04/04/2023 10:28:15
RECEIVED : 04/04/2023 10:30:05
REPORTED : 05/04/2023 15:33:27

| Test Report Status | Final | Results | Biological Reference Interval | Units |
|--------------------|-------|---------|-------------------------------|-------|
|--------------------|-------|---------|-------------------------------|-------|

SPECIALISED CHEMISTRY - HORMONE

MEDI WHEEL FULL BODY HEALTH CHECK UP BELOW 40 MALE

THYROID PANEL, SERUM

| | | | |
|---|-------|---------------|--------|
| T3 | 93.6 | 80.0 - 200.0 | ng/dL |
| METHOD : COMPETITIVE ELECTROCHEMILUMINESCENCE IMMUNOASSAY | | | |
| T4 | 8.22 | 5.10 - 14.10 | µg/dL |
| METHOD : COMPETITIVE ELECTROCHEMILUMINESCENCE IMMUNOASSAY | | | |
| TSH (ULTRASENSITIVE) | 1.780 | 0.270 - 4.200 | µIU/mL |
| METHOD : SANDWICH ELECTROCHEMILUMINESCENCE IMMUNOASSAY | | | |

Interpretation(s)

Triiodothyronine T3 , Thyroxine T4, and Thyroid Stimulating Hormone TSH are thyroid hormones which affect almost every physiological process in the body, including growth, development, metabolism, body temperature, and heart rate.

Production of T3 and its prohormone thyroxine (T4) is activated by thyroid-stimulating hormone (TSH), which is released from the pituitary gland. Elevated concentrations of T3, and T4 in the blood inhibit the production of TSH.

Excessive secretion of thyroxine in the body is hyperthyroidism, and deficient secretion is called hypothyroidism.

In primary hypothyroidism, TSH levels are significantly elevated, while in secondary and tertiary hyperthyroidism, TSH levels are low. Below mentioned are the guidelines for Pregnancy related reference ranges for Total T4, TSH & Total T3. Measurement of the serum TT3 level is a more sensitive test for the diagnosis of hyperthyroidism, and measurement of TT4 is more useful in the diagnosis of hypothyroidism. Most of the thyroid hormone in blood is bound to transport proteins. Only a very small fraction of the circulating hormone is free and biologically active. It is advisable to detect Free T3, FreeT4 along with TSH, instead of testing for albumin bound Total T3, Total T4.

| Sr. No. | TSH | Total T4 | FT4 | Total T3 | Possible Conditions |
|---------|------------|----------|--------|----------|--|
| 1 | High | Low | Low | Low | (1) Primary Hypothyroidism (2) Chronic autoimmune Thyroiditis (3) Post Thyroidectomy (4) Post Radio-Iodine treatment |
| 2 | High | Normal | Normal | Normal | (1) Subclinical Hypothyroidism (2) Patient with insufficient thyroid hormone replacement therapy (3) In cases of Autoimmune/Hashimoto thyroiditis (4). Isolated increase in TSH levels can be due to Subclinical inflammation, drugs like amphetamines, Iodine containing drug and dopamine antagonist e.g. domperidone and other physiological reasons. |
| 3 | Normal/Low | Low | Low | Low | (1) Secondary and Tertiary Hypothyroidism |
| 4 | Low | High | High | High | (1) Primary Hyperthyroidism (Graves Disease) (2) Multinodular Goitre (3) Toxic Nodular Goitre (4) Thyroiditis (5) Over treatment of thyroid hormone (6) Drug effect e.g. Glucocorticoids, dopamine, T4 replacement therapy (7) First trimester of Pregnancy |
| 5 | Low | Normal | Normal | Normal | (1) Subclinical Hyperthyroidism |
| 6 | High | High | High | High | (1) TSH secreting pituitary adenoma (2) TRH secreting tumor |
| 7 | Low | Low | Low | Low | (1) Central Hypothyroidism (2) Euthyroid sick syndrome (3) Recent treatment for Hyperthyroidism |

S.S. Wadalkar

Dr. Sneha Wadalkar, M.D
(Reg.no.MMC2012/06/1868)
Junior Biochemist



View Details



View Report

PERFORMED AT :

SRL Ltd
PRIME SQUARE BUILDING, PLOT NO 1, GAIWADI INDUSTRIAL ESTATE, S.V. ROAD, GOREGAON (W)
Mumbai, 400062
MAHARASHTRA, INDIA
Tel : 9111591115, Fax :
CIN - U74899PB1995PLC045956



Patient Ref. No. 2000011707303



MC-2010

PATIENT NAME : DINESH JHA

REF. DOCTOR : SELF

400089
Mumbai 400089ACCESSION NO : **0002WD005640**

PATIENT ID : DINEM05108827

CLIENT PATIENT ID:

ABHA NO :

AGE/SEX : 34 Years Male

DRAWN : 04/04/2023 10:28:15

RECEIVED : 04/04/2023 10:30:05

REPORTED : 05/04/2023 15:33:27

| Test Report Status | Final | Results | Biological Reference Interval | Units |
|--------------------|-------|---------|-------------------------------|-------|
|--------------------|-------|---------|-------------------------------|-------|

| | | | | | |
|---|------------|--------|--------|--------|--|
| 8 | Normal/Low | Normal | Normal | High | (1) T3 thyrotoxicosis (2) Non-Thyroidal illness |
| 9 | Low | High | High | Normal | (1) T4 Ingestion (2) Thyroiditis (3) Interfering Anti TPO antibodies |

REF: 1. TIETZ Fundamentals of Clinical chemistry 2.Guidlines of the American Thyroid association during pregnancy and Postpartum, 2011.

NOTE: It is advisable to detect Free T3,FreeT4 along with TSH, instead of testing for albumin bound Total T3, Total T4.TSH is not affected by variation in thyroid - binding protein. TSH has a diurnal rhythm, with peaks at 2:00 - 4:00 a.m. And troughs at 5:00 - 6:00 p.m. With ultradian variations.

****End Of Report****Please visit www.srlworld.com for related Test Information for this accession**CONDITIONS OF LABORATORY TESTING & REPORTING**

1. It is presumed that the test sample belongs to the patient named or identified in the test requisition form.
2. All tests are performed and reported as per the turnaround time stated in the SRL Directory of Services.
3. Result delays could occur due to unforeseen circumstances such as non-availability of kits / equipment breakdown / natural calamities / technical downtime or any other unforeseen event.
4. A requested test might not be performed if:
 - i. Specimen received is insufficient or inappropriate
 - ii. Specimen quality is unsatisfactory
 - iii. Incorrect specimen type
 - iv. Discrepancy between identification on specimen container label and test requisition form
5. SRL confirms that all tests have been performed or assayed with highest quality standards, clinical safety & technical integrity.
6. Laboratory results should not be interpreted in isolation; it must be correlated with clinical information and be interpreted by registered medical practitioners only to determine final diagnosis.
7. Test results may vary based on time of collection, physiological condition of the patient, current medication or nutritional and dietary changes. Please consult your doctor or call us for any clarification.
8. Test results cannot be used for Medico legal purposes.
9. In case of queries please call customer care (91115 91115) within 48 hours of the report.

SRL LimitedFortis Hospital, Sector 62, Phase VIII,
Mohali 160062

Dr. Sneha Wadalkar, M.D
(Reg.no.MMC2012/06/1868)
Junior Biochemist

Page 24 Of 24



View Details



View Report

PERFORMED AT :

SRL Ltd
PRIME SQUARE BUILDING,PLOT NO 1,GAIWADI INDUSTRIAL ESTATE,S.V. ROAD,GOREGAON (W)
Mumbai, 400062
MAHARASHTRA, INDIA
Tel : 9111591115, Fax :
CIN - U74899PB1995PLC045956

**Patient Ref. No. 2000011707303**